Document is current
Any future updates will be listed below
-
Authors
Atreya, Mihir R.
Cvijanovich, Natalie Z.
Fitzgerald, Julie C.
Weiss, Scott L.
Bigham, Michael T.
Jain, Parag N.
Schwarz, Adam J.
Lutfi, Riad
Nowak, Jeffrey
Allen, Geoffrey L.
Thomas, Neal J.
Grunwell, Jocelyn R.
Baines, Torrey
Quasney, Michael
Haileselassie, Bereketeab
Alder, Matthew N.
Lahni, Patrick
Ripberger, Scarlett
Ekunwe, Adesuwa
Campbell, Kyle R.
Walley, Keith R.
Standage, Stephen W.
-
Funding
Funding for this research was provided by:
Cincinnati Children’s Research Foundation (Procter K-to-R Transition Award)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (R21HD092896)
National Institute of General Medical Sciences (R35 GM126943)
- License Information
-
More Information
Article History
Received: 27 January 2023
Accepted: 19 June 2023
First Online: 26 June 2023
Declarations
:
: Keith R. Walley and the University of British Columbia hold patents for the use of human anti-PCSK9 antibody as a sepsis therapeutic.
: Informed consent was obtained from the parent or guardian of patients. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review boards of participating institutions and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: K.R.W and the University of British Columbia hold patents for the use of human anti-PCSK9 antibody as a sepsis therapeutic.
